港股異動丨李氏大藥廠(0950.HK)漲超7% 旗下兆科眼科完成1.45億美元戰略融資
格隆匯10月14日丨李氏大藥廠(0950.HK)今日續漲,現報5.6港元,漲7.69%,最新總市值32.9億港元。李氏大藥廠近日宣佈,於10月9日,公司聯營公司Zhaoke Ophthalmology Limited、公司及該等投資者等訂約各方訂立認購協議,據此,目標公司將向各名該等投資者發行及出售,而各名該等投資者則將向目標公司認購及購買B系列認購股份,總代價約為1.45億美元。認購事項由Hillhouse COFL及TPG Asia聯席牽頭,並由正心谷資本及其他私募股權公司共同牽頭,而A系列優先股大部份股東亦參與認購事項。此外據悉,公司曾公佈中期純利9698.2萬港元,同比大增153.3%;基本每股盈利16.49港仙。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.